{"id":"adebrelimab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the PD-L1/PD-1 axis, adebrelimab removes the inhibitory signal that tumors use to evade immune surveillance, allowing T cells and other immune effectors to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-L1 inhibitors and represents a form of immune checkpoint inhibition used in cancer immunotherapy.","oneSentence":"Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:47.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07071714","phase":"PHASE2","title":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-22","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT07464327","phase":"PHASE3","title":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":450},{"nctId":"NCT07393542","phase":"PHASE3","title":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-02-12","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":462},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":"Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events","enrollment":25},{"nctId":"NCT07118527","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-18","conditions":"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":600},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT07357532","phase":"PHASE2","title":"Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-01-31","conditions":"Small Cell Lung Carcinoma","enrollment":44},{"nctId":"NCT07296341","phase":"PHASE1, PHASE2","title":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2026-01-08","conditions":"Locally Advanced or Metastatic Pancreatic Cancer With","enrollment":60},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT07309185","phase":"PHASE2","title":"Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2024-07-24","conditions":"Stomach Neoplasms","enrollment":66},{"nctId":"NCT06512051","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-07-30","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":248},{"nctId":"NCT07284992","phase":"PHASE2","title":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-09-12","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":208},{"nctId":"NCT07232849","phase":"PHASE2","title":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-04","conditions":"Lung Cancer","enrollment":100},{"nctId":"NCT06703177","phase":"PHASE1, PHASE2","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-18","conditions":"Advanced Solid Tumors","enrollment":876},{"nctId":"NCT07168200","phase":"PHASE3","title":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-10-17","conditions":"Advanced Cervical Cancer","enrollment":720},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT06385678","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-05","conditions":"Advanced KRAS G12D Mutant Solid Tumors","enrollment":47},{"nctId":"NCT06247956","phase":"PHASE2","title":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-11","conditions":"Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma","enrollment":153},{"nctId":"NCT07059221","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-11","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT07069270","phase":"PHASE2","title":"A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Vunakizumab, Adebrelimab, Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT06819319","phase":"PHASE2","title":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-23","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":52},{"nctId":"NCT06879145","phase":"PHASE2, PHASE3","title":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-25","conditions":"Muscular Invasive Bladder Cancer (MIBC)","enrollment":840},{"nctId":"NCT06618664","phase":"PHASE3","title":"Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-10-28","conditions":"Advanced Hepatocellular Carcinoma","enrollment":590},{"nctId":"NCT06483282","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jin Ying","startDate":"2024-06-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":38},{"nctId":"NCT06844474","phase":"PHASE2","title":"A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-07","conditions":"NSCLC","enrollment":300},{"nctId":"NCT06282445","phase":"PHASE2","title":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-03-01","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06786312","phase":"PHASE2","title":"A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-01-25","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":34},{"nctId":"NCT06776770","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer","status":"RECRUITING","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2024-08-03","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT06765616","phase":"PHASE2","title":"Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Feng Tian","startDate":"2024-01-01","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":31},{"nctId":"NCT06480864","phase":"NA","title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-08-09","conditions":"Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT06474468","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Advanced or Metastatic Esophageal Cancer","enrollment":148},{"nctId":"NCT06417554","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-05-13","conditions":"Advanced Solid Tumors","enrollment":80},{"nctId":"NCT06237257","phase":"PHASE2","title":"A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-03-20","conditions":"Locally Advanced Cervical Cancer","enrollment":56},{"nctId":"NCT06340230","phase":"PHASE2","title":"SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2024-08-23","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":93},{"nctId":"NCT06639347","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-04","conditions":"Advanced Urothelial Carcinoma","enrollment":90},{"nctId":"NCT06589778","phase":"PHASE1, PHASE2","title":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-09-27","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT06614621","phase":"PHASE2","title":"A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-02-01","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT03736863","phase":"PHASE2","title":"A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2019-12-05","conditions":"Esophageal Cancer","enrollment":147},{"nctId":"NCT06599775","phase":"PHASE2","title":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-10","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT06592625","phase":"PHASE2","title":"Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-09-20","conditions":"Untreated Early-stage or Locally Advanced Breast Cancer","enrollment":60},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT06530797","phase":"","title":"A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-08-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":2000},{"nctId":"NCT06531278","phase":"PHASE2","title":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety","status":"RECRUITING","sponsor":"Jiang Long","startDate":"2024-07-16","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":40},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06508229","phase":"PHASE2","title":"Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":65},{"nctId":"NCT06439589","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-12","conditions":"Advanced Solid Tumors","enrollment":88},{"nctId":"NCT06480136","phase":"PHASE2","title":"SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-07-15","conditions":"NSCLC","enrollment":32},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT06415669","phase":"PHASE2","title":"A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-05-19","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06181032","phase":"PHASE1","title":"A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2023-12-23","conditions":"Biliary Tract Malignancies","enrollment":35},{"nctId":"NCT06375317","phase":"PHASE2","title":"HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Yehua Shen","startDate":"2024-04-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06149130","phase":"PHASE2","title":"Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-01-11","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT06339216","phase":"PHASE2","title":"A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-03-20","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT06299371","phase":"PHASE2","title":"Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2024-04-15","conditions":"Non Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06266832","phase":"PHASE2","title":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Rectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06149767","phase":"PHASE2","title":"Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-01","conditions":"Cervical Cancer","enrollment":26},{"nctId":"NCT06092268","phase":"PHASE1, PHASE2","title":"A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-10","conditions":"Advanced Solid Tumors","enrollment":270},{"nctId":"NCT05353361","phase":"PHASE2","title":"A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":402},{"nctId":"NCT05738317","phase":"PHASE2","title":"Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment","status":"UNKNOWN","sponsor":"Xiaorong Dong","startDate":"2022-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":45},{"nctId":"NCT05416775","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-08-15","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ai Rui Li","SHR-1316"],"phase":"phase_3","status":"active","brandName":"Adebrelimab injection","genericName":"Adebrelimab injection","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}